Rentschler Biopharma Inc. Recognized as Central Massachusetts Manufacturer of the Year
- The company was recognized by the state’s Legislative Manufacturing Caucus for its exceptional leadership and contributions to the manufacturing sector.
- A cutting-edge production line is attracting new clients, initiating new projects, and addressing new indications.
LAUPHEIM, Germany and MILFORD, Mass., Oct. 23, 2025 — Rentschler Biopharma, a prominent global contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, announced today that its U.S. affiliate, Rentschler Biopharma Inc., has been designated as the Manufacturer of the Year for Central Massachusetts, encompassing all industries.
The accolade was conferred at the 10th Annual Manufacturing Awards Ceremony, organized by the state’s Legislative Manufacturing Caucus, held on October 21, 2025, at Gillette Stadium in Foxborough, MA. This event celebrated manufacturers from across the state for their significant leadership roles and input into the manufacturing sector. Massachusetts has emerged as a formidable leader in advanced manufacturing, and the ceremony highlighted this accomplishment, stressing the ongoing need for collaboration between government and industry to foster innovation.
State Senator Becca Rausch, who put forward Rentschler Biopharma for the award, commented: “I am pleased to nominate Rentschler Biopharma for the 10th Annual Massachusetts Manufacturing Awards. Through partnerships with state and local entities, Rentschler Biopharma has created opportunities for local residents to pursue careers in life sciences and biotech manufacturing, and their advanced facility in Milford generates valuable jobs for the MetroWest area. Furthermore, Rentschler Biopharma acts as a strong community partner and demonstrates a firm dedication to environmental sustainability, a commitment that gains increasing importance given the persistent effects of climate change.”
Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S., stated: “We are deeply honored to accept this award and proud to have been a part of the Massachusetts biopharma and manufacturing communities since 2019. With our recently operational new production line in Milford, we have entered an exciting phase of growth – welcoming new clients, initiating diverse projects, and enhancing our support for current international collaborators. This recognition underscores the hard work of our entire team and the robust capabilities of our U.S. operations. At Rentschler Biopharma, we are dedicated to being a reliable partner – providing consistent, top-tier solutions that empower our clients to deliver groundbreaking, life-improving treatments to patients.”
The newly established production line represents the most substantial expansion in the company’s history, spanning over 150 years. It commenced full operations last year, contributing an additional 22,000 square feet of manufacturing cleanroom space to the existing Milford facility and incorporating four 2,000 L single-use bioreactors. This landmark expansion, the largest in the company’s century-and-a-half existence, effectively doubled Rentschler Biopharma’s global cGMP capacity. The site is actively involved in the development and production of a wide array of therapeutics across various modalities and disease categories, including oncology, hematology, musculoskeletal, cardiovascular, and organ failure.
About Rentschler Biopharma SE
Rentschler Biopharma is a premier contract development and manufacturing organization (CDMO) exclusively focused on client initiatives. The company offers biopharmaceutical process development and manufacturing services, alongside related consulting, project management, and regulatory assistance. Rentschler Biopharma’s superior quality is evidenced by its extensive experience and distinguished track record as a client solution provider. A sophisticated quality management system, a well-established operational excellence philosophy, and cutting-edge technologies ensure product quality and efficiency at every stage of development and manufacturing. Rentschler Biopharma is a privately-owned company with approximately 1,400 employees, based in Laupheim, Germany, and operating in Milford, MA, USA. In 2024, the company became a signatory to the United Nations Global Compact, highlighting Rentschler Biopharma’s emphasis on sustainability. For more information about the company, please visit . Follow Rentschler Biopharma on .
Contact:
Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Global Head of Communications
Phone: +49-7392-701-467
Media inquiries:
MC Services AG
Eva Bauer
Phone: +49-89-210228-0
U.S.
Laurie Doyle
Phone: +1-339-832-0752
The Rentschler Biopharma team is honored with the Manufacturer of the Year award for Central Massachusetts. Featured here with state officials, including State Senator Paul Feeney and State Representative Jeffrey N. Roy.
